Agile Therapeutics shares were on the rise this week, rocketing nearly 300% after the women’s healthcare company said a U.S. Food and Drug Administration advisory committee voted in favor of its contraceptive patch Twirla. The FDA’s Bone, Reproductive and Urologic Drugs Advisory Committee (BRUDAC) met to discuss Agile’s New Drug Application (NDA) for Twirla, the … Continue reading “Agile Therapeutics Shares Explode as Contraceptive Patch Twirla Gets Nod from FDA”
